These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 36493574)
41. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial. Coutzac C; Bibeau F; Ben Abdelghani M; Aparicio T; Cohen R; Coquan E; Dubreuil O; Evesque L; Ghiringhelli F; Kim S; Lesourd S; Neuzillet C; Phelip JM; Piessen G; Rochigneux P; Samalin E; Soularue E; Touchefeu Y; Tougeron D; Zaanan A; de la Fouchardière C Dig Liver Dis; 2022 Oct; 54(10):1335-1341. PubMed ID: 35907691 [TBL] [Abstract][Full Text] [Related]
42. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842 [TBL] [Abstract][Full Text] [Related]
43. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Barrington DA; Dilley SE; Smith HJ; Straughn JM Gynecol Oncol; 2019 May; 153(2):381-384. PubMed ID: 30808517 [TBL] [Abstract][Full Text] [Related]
44. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches. Tan E; Sahin IH Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189 [No Abstract] [Full Text] [Related]
45. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer. Green AK; Feinberg J; Makker V Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32213091 [TBL] [Abstract][Full Text] [Related]
46. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Ackroyd SA; Huang ES; Kurnit KC; Lee NK Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196 [TBL] [Abstract][Full Text] [Related]
47. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Maio M; Ascierto PA; Manzyuk L; Motola-Kuba D; Penel N; Cassier PA; Bariani GM; De Jesus Acosta A; Doi T; Longo F; Miller WH; Oh DY; Gottfried M; Xu L; Jin F; Norwood K; Marabelle A Ann Oncol; 2022 Sep; 33(9):929-938. PubMed ID: 35680043 [TBL] [Abstract][Full Text] [Related]
48. Immunotherapy of MSI Cancer: Facts and Hopes. Wilbur HC; Le DT; Agarwal P Clin Cancer Res; 2024 Apr; 30(8):1438-1447. PubMed ID: 38015720 [TBL] [Abstract][Full Text] [Related]
49. Current and emerging immunotherapeutic approaches for biliary tract cancers. Yuan ZG; Zeng TM; Tao CJ Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807 [TBL] [Abstract][Full Text] [Related]
50. Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H). Liao Y; Zhu C; Song X; Ruan J; Ding Y; Chen Y; Yang Q Med Sci Monit; 2022 Mar; 28():e934493. PubMed ID: 35322001 [TBL] [Abstract][Full Text] [Related]
51. Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma. Ma YT; Yang HL; Yan L; Hua F; Wang DG; Xu GY; Li Y; Xue YJ; Qin YJ; Sha D; Ning H; Zhao MQ; Yao ZG Pathol Oncol Res; 2022; 28():1610638. PubMed ID: 36338826 [TBL] [Abstract][Full Text] [Related]
52. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience. Coston T; Desai A; Babiker H; Sonbol MB; Chakrabarti S; Mahipal A; McWilliams R; Ma WW; Bekaii-Saab TS; Stauffer J; Starr JS JCO Precis Oncol; 2023 Aug; 7():e2200706. PubMed ID: 37625102 [TBL] [Abstract][Full Text] [Related]
53. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636 [TBL] [Abstract][Full Text] [Related]
54. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494 [TBL] [Abstract][Full Text] [Related]
55. Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities. Rizzo A J Clin Med; 2022 Jul; 11(13):. PubMed ID: 35807197 [TBL] [Abstract][Full Text] [Related]
56. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer. Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ Front Immunol; 2019; 10():3023. PubMed ID: 31998307 [TBL] [Abstract][Full Text] [Related]
57. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched. Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649 [TBL] [Abstract][Full Text] [Related]
58. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial. André T; Berton D; Curigliano G; Sabatier R; Tinker AV; Oaknin A; Ellard S; de Braud F; Arkenau HT; Trigo J; Gravina A; Kristeleit R; Moreno V; Abdeddaim C; Vano YA; Samouëlian V; Miller R; Boni V; Torres AA; Gilbert L; Brown J; Dewal N; Dabrowski C; Antony G; Zografos E; Veneris J; Banerjee S JAMA Netw Open; 2023 Nov; 6(11):e2341165. PubMed ID: 37917058 [TBL] [Abstract][Full Text] [Related]
60. Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue "Diagnosis and Management of Endometrial Cancer". Gadducci A; Cosio S Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944775 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]